Results 301 to 310 of about 10,512,482 (403)

Retraction notice to: Gallstone ileus without bilioenteric fistula years after bypass surgery for Crohn's disease. Case report and clues to etiology of a neglected cause of obstruction [IJSCR Volume 9, 2015, Pages 134–138]

, 2016
Gianluca Pellino, Giuseppe Candilio, G. Serena De Fatico, Rosa Marcellinaro, Giulio C Formicola, Antonio Volpicelli, Guido Sciaudone, Gabriele Riegler, Silvestro Canonico, Francesco Selvaggi   +9 more
openalex   +1 more source

Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility

Nature Genetics, 2007
M. Parkes, J. Barrett, N. Prescott, M. Tremelling, C. Anderson, S. Fisher, R. Roberts, E. Nimmo, Fraser Cummings, D. Soars, H. Drummond, C. Lees, S. Khawaja, R. Bagnall, D. Burke, Catherine E. Todhunter, Tariq Ahmad, Clive M. Onnie, W. McArdle, D. Strachan, G. Bethel, C. Bryan, C. Lewis, P. Deloukas, A. Forbes, J. Sanderson, D. Jewell, J. Satsangi, J. Mansfield, L. Cardon, C. Mathew   +30 more
semanticscholar   +1 more source

Appendiceal Crohn's Disease Manifesting as Appendiceal Malignancy: A Case Report and Review of the Literature

The Kaohsiung Journal of Medical Sciences, EarlyView.
Ming‐Jung Meng, Tai‐Di Chen, Puo‐Hsien Le, Chia‐Jung Kuo   +3 more
wiley   +1 more source

Effectiveness and Safety of Setmelanotide in a Patient With a Heterozygous PCSK1 Deficiency

Obesity, EarlyView.
ABSTRACT Setmelanotide, a melanocortin 4 receptor (MC4R) agonist, is a promising pharmacological treatment option for people with rare monogenic obesity conditions affecting the leptin‐melanocortin signaling pathway, including proprotein convertase subtilisin/kexin type 1 (PCSK1) gene mutations.
Ellina Lytvyak, Arshdeep Rattol, Eduardo Grunvald   +2 more
wiley   +1 more source

Perioperative utilization of JAK inhibitors in Perianal Fistulizing Crohn's disease. [PDF]

JPGN Rep
Lyons A, Lawrence L, Saul S.
europepmc   +1 more source

[A case report of Crohn's disease in a child treated with upadacitinib]. [PDF]

Zhongguo Dang Dai Er Ke Za Zhi
Pan GX, Yang QP, Yang XM, Cai Y, Li ST.
europepmc   +1 more source

W1258 Relationship Between Thiopurine Metabolite Levels and Endoscopic Improvement in Patients With Postoperative Moderate to Severe Endoscopic Recurrence of Crohn's Disease

, 2010
Sieglinde Angelberger, Elke Schaeffeler, Alexander Teml, Wolfgang Petritsch, Olga Shonová, Milan Lukáš, Simon Bar–Meir, Roland Greinwald, Ralph Müeller, Eduard F. Stange, Klaus Herrlinger, Matthias Schwab, Walter Reinisch   +12 more
openalex   +1 more source

The General Disease Factor (“d”): First Empirical Evidence From China

Med Research, EarlyView.
Hongyi Sun, Qinghuan He, Ting Su, Xiaoli Yang, Zhiwei Zhou   +4 more
wiley   +1 more source

The N‐Glycome to Differentiate Mesenchymal Stem Cells Upon Chondrogenic Differentiation, Dedifferentiation, and Senescence

PROTEOMICS, EarlyView.
ABSTRACT Mesenchymal stem cells (MSCs) are adult stem cells able to self‐renewal or differentiation into different cell types, including chondrocytes. N‐Glycans are post‐translational modifications of glycoproteins that contribute to vital cell functions.
Houda Montacir, Karina Biskup, Michael Sittinger, Rudolf Tauber, Véronique Blanchard   +4 more
wiley   +1 more source

Mirikizumab pharmacokinetics and exposure–response in pediatric patients with moderate‐to‐severe ulcerative colitis

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 474-485, March 2025.
Abstract Mirikizumab is a p19‐directed anti‐interleukin‐23 antibody approved for the treatment of adults with moderate‐to‐severe ulcerative colitis (UC). Here, we report the first data of mirikizumab pharmacokinetics (PK) and exposure–response (E/R) relationships in pediatric participants (aged 2 to <18 years weighing >10 kg) with moderate‐to‐severe UC
Yuki Otani, Laiyi Chua, Wendy J. Komocsar, Amy Larkin, Jordan Johns, Xin Zhang   +5 more
wiley   +1 more source